gastrointestinal stromal tumors

GPTKB entity

Statements (59)
Predicate Object
gptkbp:instance_of gptkb:Oncology
gptkbp:associated_with gastrointestinal tract
gptkbp:characterized_by mutations in KIT or PDGFRA genes
gptkbp:clinical_trial ongoing studies
phase II trials
phase III trials
gptkbp:death approximately 5-year survival rate varies
higher in localized disease
lower in metastatic disease
gptkbp:demographics more common in adults
rare in children
gptkbp:diagnosis gptkb:MRI
CT scan
biopsy
endoscopy
depends on tumor size and mitotic index
gptkbp:diseases epithelioid type
mixed type
spindle cell type
gptkbp:events clinical evaluations
regular imaging studies
gptkbp:financial_support counseling services available
educational resources available
support groups available
gptkbp:genetic_studies gain-of-function mutations
gptkbp:genetic_syndrome_association associated with Carney-Stratakis syndrome
associated with familial GIST syndrome
gptkbp:historical_context first described in 1983
previously thought to be leiomyomas
recognized as distinct entity in 2000s
https://www.w3.org/2000/01/rdf-schema#label gastrointestinal stromal tumors
gptkbp:imaging_findings may have calcifications
may have necrosis
may show heterogeneous enhancement
gptkbp:is_located_in stomach
small intestine
gptkbp:occurs_in approximately 10-20 per million people
gptkbp:origin gptkb:interstitial_cells_of_Cajal
gptkbp:research_focus biomarkers
targeted therapies
genetic profiling
gptkbp:risk_factor gptkb:neurofibromatosis_type_1
gptkb:Carney_triad
age
family history of GIST
gptkbp:scientific_classification benign
malignant
gptkbp:symptoms gptkb:anemia
nausea
abdominal pain
vomiting
gptkbp:treatment gptkb:imatinib
gptkb:sunitinib
gptkb:surgery
variable response to therapy
gptkbp:treatment_resistance can develop resistance to imatinib
can develop resistance to sunitinib
gptkbp:bfsParent gptkb:Gleevec
gptkbp:bfsLayer 5